Pyxis Oncology, Inc. (NASDAQ:PYXS) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock or pre-funded warrants with accompanying common warrants Closed: US$110M raised · US$2.9 a share · Warrants at US$3.5 · Leerink Partners +2 Dealers: Leerink Partners (co-lead), Guggenheim Securities (co-lead), Wells Fargo Securities (co-lead) Buyers: OrbiMed; GordonMD Global Investments; BVF Partners; Coastlands Capital; RTW Investments Use of proceeds: Advance lead program MICVO through key clinical milestones including planned Phase 3 Headliner trial, plus working capital and general corporate purposes | Oct 2, 2026 |
| Private placement of securities with accompanying warrants Closed: US$50M raised Use of proceeds: Advance MICVO through key clinical milestones and continue patient follow-up so data can mature | Aug 13, 2026 |
| Private placement of common stock and warrants Announced: about US$50M · US$2.551 a share · Warrants at US$3.289 · Wells Fargo Securities Dealers: Wells Fargo Securities (lead) Buyers: BVF Partners L.P. (led the financing); GordonMD Global Investments; RTW Investments; Coastlands Capital Use of proceeds: Extend cash runway into Q2 2027 and advance lead clinical program MICVO through key clinical milestones | Jun 30, 2026 |